A Study on Ubiquinol on Fatigue and Muscle Strength in Healthy Adults Taking GLP-1 Agonists

NCT07789106 | Not Yet Recruiting

• 1 other identifier: SSG-26-002-001
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if a daily ubiquinol supplement can reduce fatigue and help maintain muscle strength in adults aged 30-65 who are taking a GLP-1 weight loss medication (Wegovy® or Mounjaro®). Ubiquinol is a form of Coenzyme Q10 (CoQ10), a substance the body makes naturally that plays a key role in energy production. The main questions it aims to answer are: Does ubiquinol lower fatigue levels compared to a placebo (a look-alike capsule that contains no ubiquinol)? Does ubiquinol help maintain muscle strength during weight loss treatment? Researchers will compare ubiquinol to a placebo to see if ubiquinol helps with fatigue and muscle strength in people using GLP-1 medications. Participants will: Take one ubiquinol (100 mg) or placebo capsule every day for 9 months Have a nurse visit their home 4 times (at months 0, 3, 6, and 9) to take a small blood sample, measure their body, and supervise a simple sit-to-stand exercise test Attend a short monthly video call (about 20-30 minutes) with a study dietitian Complete questionnaires and 4 days of diet logging every 3 months using a smartphone app Log all exercise sessions in the smartphone app throughout the study This is a fully remote study - participants do not need to visit a clinic. About 90 people will take part.

Conditions

Obesity & Overweight; GLP - 1; Fatigue Severity Scale; Ubiquinol; Muscle Contraction

Outcome Measures

Primary Outcomes (1)

• Self-reported fatigue

  Measured via Chalder Fatigue Scale score

  9 months

Secondary Outcomes (18)

• Quality of life questionnaire

  9 months

• Skeletal muscle function

  9 months

• Body Mass

  9 months

• Blood pyruvate levels

  9 months

• Blood Lactate levels

  9 months

Study Arms (2)

Ubiquinol

EXPERIMENTAL

Dietary Supplement: Ubiquinol 100 MG Oral Capsule

Placebo

PLACEBO COMPARATOR

Dietary Supplement: Placebo

Interventions

Ubiquinol 100 MG Oral Capsule DIETARY_SUPPLEMENT

The active intervention is a commercially available ubiquinol dietary supplement, manufactured and supplied by Kaneka (Japan). The dose is one 100mg capsule per day taken.

Ubiquinol

Placebo DIETARY_SUPPLEMENT

The placebo is manufactured by the same manufacturer that produces the active product (Kaneka, Japan). The placebo is visually similar to the active product and will be packaged in the same bottles as the active intervention to maintain the blind. The dose is one 100mg capsule per day taken with the first meal of the day. The product is stored at room temperature.

Placebo

Eligibility Criteria

• Age: 30 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 30-65 years
• Body mass index \>27kg/m2 and \<35 kg/m2
• Currently initiating, or has initiated within the preceding 4 weeks of screening, one of the following MHRA-licensed weight management pharmacotherapies: semaglutide 2.4mg (Wegovy®) or tirzepatide (Mounjaro®) prescribed for the indication of weight management.
• Is physically mobile and able to complete 5x sit to stand movements
• Owns a smartphone (iOS 15.6 or later, Android 9 or later) and is willing and able to install the SANNO Health app
• Proficient in English language speaking and reading
• Owns their own digital body weighing scale
• Able and willing to provide full informed consent

You may not qualify if:

• Prior use of ubiquinol or Co-enzyme Q10 within 3 months of screening
• Diagnosed condition which, in the opinion of the Chief investigator, may independently impact fatigue (e.g. type 1 or type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, inflammatory or autoimmune conditions, cirrhotic or advanced liver disease, malignancy)
• Prior or current use of statin medication
• Has previously used GLP-1 agonists and/or undergone bariatric surgery
• Other medications, which in the opinion of the Chief Investigator, may deplete CoQ10
• Failed screening bloods (any results that is outside of the lab reference range)
• Intention to stop GLP-1 agonist use within 9 months of randomisation
• Pregnancy, breastfeeding or intention to conceive during study

Sponsors & Collaborators

• StudySetGo: lead

Study Sites (1)

Office 1110 3 Fitzroy Place, 1/1, Sauchiehall Street

Glasgow, G3 7RH, United Kingdom

Location

MeSH Terms

Conditions

Obesity; Overweight

Interventions

ubiquinol

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Tom Jameson, PhD

CONTACT

7794865520; tom.jameson@studysetgo.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2026
• First Posted: August 27, 2026
• Study Start (Estimated): September 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): September 1, 2028
• Last Updated: August 27, 2026

Record last verified: 2026-08

Locations

GB (1)